Dakota Wealth Management Reduces Stock Holdings in Pfizer Inc. $PFE

Key Points

• Dakota Wealth Management reduced its stake in Pfizer Inc. by 5.7% during the second quarter, selling 15,648 shares and now holding 261,078 shares worth approximately $6.33 million.
• Notable institutional investors have significantly increased their holdings in Pfizer, with Pacer Advisors boosting their position by 856.8%, now owning over 20 million shares valued at $508 million.
• Pfizer reported earnings per share of $0.78 for the last quarter, surpassing analyst estimates, and set its fiscal year 2025 guidance between $2.900-$3.100 EPS.

Dakota Wealth Management reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 261,078 shares of the biopharmaceutical company's stock after selling 15,648 shares during the quarter. Dakota Wealth Management's holdings in Pfizer were worth $6,329,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pacer Advisors Inc. boosted its position in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Amundi lifted its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Nuveen LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. grew its stake in Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after purchasing an additional 9,041,990 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 2.0%

Shares of NYSE:PFE opened at $23.61 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a market cap of $134.25 billion, a P/E ratio of 12.56, a PEG ratio of 0.78 and a beta of 0.55. The stock's fifty day moving average price is $24.57 and its 200-day moving average price is $24.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on PFE shares. Berenberg Bank dropped their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.